The Inhibition of Complement System in Formal and Emerging Indications: Results from Parallel One-Stage Pairwise and Network Meta-Analyses of Clinical Trials and Real-Life Data Studies
Authors:
- Coralina Bernuy-GuevaraCoralina Bernuy-Guevara
- Hassib ChehadeHCHassib Chehade
- Yannick D. MullerYMYannick D. Muller
- Julien VionnetJVJulien Vionnet
- François CachatFCFrançois Cachat
- Gabriella GuzzoGGGabriella Guzzo
- Carlos Ochoa-SangradorCOCarlos Ochoa-Sangrador
- F. Javier ÁlvarezF. Javier Álvarez
- Daniel TetaDTDaniel Teta
- Débora Martín-GarcíaDMDébora Martín-García
- Marcel AdlerMAMarcel Adler
- Félix J. de PazFPFélix J. de Paz
Open Access
- 16 September 2020
- journal article
- research article
- Published by MDPI AG in Biomedicines
- Vol. 8 (9) , 355
Abstract
This manuscript presents quantitative findings on the actual effectiveness of terminal complement component 5 (C5) inhibitors and complement component 1 (C1) esterase inhibitors through their formal and common “off-label” (compassionate) indications. The results emanated from pairwise and network meta-analyses to present evidence until September 2019. Clinical trials (CT) and real-life non-randomized studies of the effects of interventions (NRSI) are consistent on the benefits of C5 inhibitors and of the absence of effects of C1 esterase inhibitors (n = 7484): Mathematically, eculizumab (surface under the cumulative ranking area (SUCRA) >0.6) and ravulizumab (SUCRA ≥ 0.7) were similar in terms of their protective effect on hemolysis in paroxysmal nocturnal hemoglobinuria (PNH), thrombotic microangiopathy (TMA) in atypical hemolytic uremic syndrome (aHUS), and acute kidney injury (AKI) in aHUS, in comparison to pre-/off-treatment state and/or placebo (SUCRA < 0.01), and eculizumab was efficacious on thrombotic events in PNH (odds ratio (OR)/95% confidence interval (95% CI) in CT and real-life NRSI, 0.07/0.03 to 0.19, 0.24/0.17 to 0.33) and chronic kidney disease (CKD) occurrence/progression in PNH (0.31/0.10 to 0.97, 0.66/0.44 to 0.98). In addition, meta-analysis on clinical trials shows that eculizumab mitigates a refractory generalized myasthenia gravis (rgMG) crisis (0.29/0.13 to 0.61) and prevents new acute antibody-mediated rejection (AMR) episodes in kidney transplant recipients (0.25/0.13 to 0.49). The update of findings from this meta-analysis will be useful to promote a better use of complement inhibitors, and to achieve personalization of treatments with this class of drugs.Keywords
This publication has 90 references indexed in Scilit:
- Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic–Uremic SyndromeNew England Journal of Medicine, 2013
- Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuriaBritish Journal of Haematology, 2013
- Eculizumab for Atypical Hemolytic Uremic Syndrome Recurrence in Renal TransplantationAmerican Journal of Transplantation, 2012
- Complement: a key system for immune surveillance and homeostasisNature Immunology, 2010
- Long‐term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuriaAmerican Journal of Hematology, 2010
- Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategoriesBlood, 2008
- Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuriaBlood, 2008
- Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuriaBlood, 2007
- Epidemiology and Reporting Characteristics of Systematic ReviewsPLOS Medicine, 2007
- Measuring inconsistency in meta-analysesBMJ, 2003